Fresenius Expects 2026 Core EPS Growth in Upper Half of 10%-15% Range at Constant Currency
Bitget2026/11/04 06:00Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
- Fresenius expects fiscal 2026 core earnings per share growth in the upper half of its 10%-15% range at constant currencies.
- Group EBIT margin is now expected above 11.5%, compared with previous expectations of around 11.5%.
- Kabi’s EBIT margin is forecast at the upper end of 16.5%-17%, with mid- to high-single-digit organic revenue growth.
- Helios expects an EBIT margin of 10%-10.5%, with mid-single-digit organic revenue growth.
- Third-quarter core EPS rose 14% at constant currencies; group EBIT margin expanded 50 basis points to 11%.
Disclaimer:
This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
格隆汇•2026/11/09 07:01

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
智通财经•2026/11/09 06:41

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
智通财经•2026/11/09 06:41

Crypto prices
MoreBitcoin
BTC
$73,942.18
-2.38%
Ethereum
ETH
$2,092.64
-6.25%
Tether USDt
USDT
$0.9987
+0.02%
BNB
BNB
$677.68
-2.86%
USDC
USDC
$0.9998
+0.00%
XRP
XRP
$1.09
-6.43%
Solana
SOL
$85.49
-3.96%
TRON
TRX
$0.3164
-1.20%
Zcash
ZEC
$1,199.7
-5.04%
Hyperliquid
HYPE
$73.48
-4.81%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now